Elena H MartÃ-nez-Lapiscina

List of Publications by Year
in descending order

77 papers	8,291 citations	159358 30 h-index	82410 72 g-index
79 all docs	79 docs citations	79 times ranked	11816 citing authors

#	Article	IF	Citations
1	Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. New England Journal of Medicine, 2013, 368, 1279-1290.	13.9	3,677
2	Mediterranean Diet and Age-Related Cognitive Decline. JAMA Internal Medicine, 2015, 175, 1094.	2.6	653
3	Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1318-1325.	0.9	534
4	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	4.9	397
5	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology, 2016, 86, 2303-2309.	1.5	331
6	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology, The, 2016, 15, 574-584.	4.9	266
7	Virgin olive oil supplementation and long-term cognition: the Predimed-Navarra randomized, trial. Journal of Nutrition, Health and Aging, 2013, 17, 544-552.	1.5	216
8	Transâ€synaptic axonal degeneration in the visual pathway in multiple sclerosis. Annals of Neurology, 2014, 75, 98-107.	2.8	206
9	Dynamics of retinal injury after acute optic neuritis. Annals of Neurology, 2015, 77, 517-528.	2.8	142
10	Mediterranean diet and the incidence of cardiovascular disease: A Spanish cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 21, 237-44.	1.1	133
11	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8463-8470.	3.3	112
12	Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Annals of Neurology, 2019, 85, 618-629.	2.8	104
13	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology, 2021, 97, 68-79.	1.5	96
14	Structural networks involved in attention and executive functions in multiple sclerosis. NeuroImage: Clinical, 2017, 13, 288-296.	1.4	87
15	Genotype patterns at CLU, CR1, PICALM and APOE, cognition and Mediterranean diet: the PREDIMED-NAVARRA trial. Genes and Nutrition, 2014, 9, 393.	1.2	58
16	Myasthenia gravis: Sleep quality, quality of life, and disease severity. Muscle and Nerve, 2012, 46, 174-180.	1.0	50
17	Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	47
18	Nut consumption and incidence of hypertension: The SUN prospective cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 359-365.	1.1	45

#	Article	IF	Citations
19	The visual pathway as a model to understand brain damage in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1678-1685.	1.4	45
20	Vitamin D, smoking, EBV, and long-term cognitive performance in MS. Neurology, 2020, 94, e1950-e1960.	1.5	45
21	Late-onset neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	44
22	Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. Therapeutic Advances in Neurological Disorders, 2016, 9, 436-440.	1.5	43
23	Monitoring the Course of MS With Optical Coherence Tomography. Current Treatment Options in Neurology, 2017, 19, 15.	0.7	40
24	Improved Framework for Tractography Reconstruction of the Optic Radiation. PLoS ONE, 2015, 10, e0137064.	1.1	39
25	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. Multiple Sclerosis Journal, 2016, 22, 564-568.	1.4	36
26	Colour vision impairment is associated with disease severity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1207-1216.	1.4	35
27	Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. Journal of Neurology, 2015, 262, 2491-2497.	1.8	35
28	Retinal periphlebitis is associated with multiple sclerosis severity. Neurology, 2013, 81, 877-881.	1.5	34
29	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987158.	0.5	34
30	Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis. Acta Neurologica Scandinavica, 2013, 128, 24-31.	1.0	33
31	Dynamics and heterogeneity of brain damage in multiple sclerosis. PLoS Computational Biology, 2017, 13, e1005757.	1.5	33
32	Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008â€“2012. Journal of Neurology, 2014, 261, 759-767.	1.8	32
33	Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis. JAMA Neurology, 2018, 75, 1246.	4.5	32
34	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain, 2020, 143, 1127-1142.	3.7	29
35	The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC Research Notes, 2014, 7, 910.	0.6	26
36	Knowledge Retrieval from PubMed Abstracts and Electronic Medical Records with the Multiple Sclerosis Ontology. PLoS ONE, 2015, 10, e0116718.	1.1	26

#	Article	IF	Citations
37	Associations of serum 25(OH) vitamin D levels with clinical and radiological outcomes in multiple sclerosis, a systematic review and meta-analysis. Journal of the Neurological Sciences, 2020, 411, 116668.	0.3	26
38	Dynamic molecular monitoring of retina inflammation by in vivo Raman spectroscopy coupled with multivariate analysis. Journal of Biophotonics, 2014, 7, 724-734.	1.1	25
39	Early retinal atrophy predicts long-term visual impairment after acute optic neuritis. Multiple Sclerosis Journal, 2018, 24, 1196-1204.	1.4	23
40	Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors. Multiple Sclerosis and Related Disorders, 2020, 38, 101483.	0.9	23
41	Retrograde retinal damage after acute optic tract lesion in MS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 824-826.	0.9	22
42	Walking function in clinical monitoring of multiple sclerosis by telemedicine. Journal of Neurology, 2015, 262, 1706-1713.	1.8	22
43	Magnetic resonance markers of tissue damage related to connectivity disruption in multiple sclerosis. NeuroImage: Clinical, 2018, 20, 161-168.	1.4	22
44	Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 9-14.	0.9	22
45	Predictors of vision impairment in Multiple Sclerosis. PLoS ONE, 2018, 13, e0195856.	1.1	21
46	Cortical fractal dimension predicts disability worsening in Multiple Sclerosis patients. NeuroImage: Clinical, 2021, 30, 102653.	1.4	21
47	Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Scientific Reports, 2020, 10, 13333.	1.6	20
48	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	0.9	18
49	Spanish validation of the telephone assessed Expanded Disability Status Scale and Patient Determined Disease Steps in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 333-339.	0.9	17
50	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	4.5	17
51	Healthy diet, depression and quality of life: A narrative review of biological mechanisms and primary prevention opportunities. World Journal of Psychiatry, 2021, 11, 997-1016.	1.3	16
52	The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis. Journal of Neuro-Ophthalmology, 2018, 38, 494-501.	0.4	15
53	Visual field impairment captures disease burden in multiple sclerosis. Journal of Neurology, 2016, 263, 695-702.	1.8	14
54	Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1234-1235.	1.4	13

#	Article	IF	Citations
55	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 188-195.	0.9	13
56	Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making. Expert Review of Precision Medicine and Drug Development, 2017, 2, 345-361.	0.4	12
57	A Healthy Diet for Your Heart and Your Brain. , 2018, , 169-197.		12
58	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open, 2020, 10, e035397.	0.8	10
59	The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity. Multiple Sclerosis and Related Disorders, 2015, 4, 387-394.	0.9	9
60	Impairment of decision-making in multiple sclerosis: A neuroeconomic approach. Multiple Sclerosis Journal, 2017, 23, 1762-1771.	1.4	8
61	Remyelination: a good neuroprotective strategy for preventing axonal degeneration?. Brain, 2019, 142, 233-236.	3.7	8
62	Impact of Cognitive Reserve and Structural Connectivity on Cognitive Performance in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 581700.	1.1	8
63	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Multiple Sclerosis Journal, 2021, 27, 1706-1716.	1.4	8
64	Dynamics and Predictors of Cognitive Impairment along the Disease Course in Multiple Sclerosis. Journal of Personalized Medicine, 2021, 11, 1107.	1.1	8
65	Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878000.	1.5	7
66	In Vivo Molecular Changes in the Retina of Patients With Multiple Sclerosis. , 2021, 62, 11.		7
67	Popularidad de NeurologÃa en EspaÃ±a: anÃ¡lisis de la elecciÃ³n de la especialidad. NeurologÃa, 2020, 35, 543-550.	0.3	6
68	Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon. Journal of the Neurological Sciences, 2018, 387, 60-69.	0.3	5
69	Reporting of R2 Statistics for Mixed-Effects Regression Modelsâ€"Reply. JAMA Neurology, 2019, 76, 507.	4.5	5
70	Phenytoin for neuroprotection. Lancet Neurology, The, 2016, 15, 901-902.	4.9	2
71	Time is vision: The importance of the early discovery and diagnosis of optic neuritis. Multiple Sclerosis Journal, 2017, 23, 1806-1807.	1.4	2
72	Epileptic seizure and lipoma of corpus callosum: cause or incidental finding. NeurologÃa (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.2	1

#	Article	IF	Citations
73	Reply to the letter to the editor by Lucena Romero et al. on the article â€œEpileptic seizure and lipoma of corpus callosum: Cause or incidental findingâ€• NeurologÃa (English Edition), 2012, 27, 58-59.	0.2	0
74	Retinal inflammation in multiple sclerosis revealed by optical coherence tomography and ophthalmoscopy. , 0, , 176-183.		0
75	Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases. , 2016, , 205-214.		0
76	Drug Trials in Neuroprotection. , 2016, , 171-184.		0
77	Trans Neuronal Retrograde Degeneration to OCT in Central Nervous System Diseases. , 2020, , 365-374.		0